Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 11.02 is 103% above its 5-year average of 5.44, near the high end of its 5-year range (2.39–11.02).
As of the fiscal period ended Tuesday, June 30, 2026. 39.43% above its 12-month average of 7.90.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 11.02.
QUICK RATIO (ACID-TEST)
11.02
QUICK RATIO (ACID-TEST) AVG TTM
7.90
QUICK RATIO (ACID-TEST) AVG 3Y
6.06
QUICK RATIO (ACID-TEST) AVG 5Y
5.44
QUICK RATIO (ACID-TEST) AVG 10Y
5.68
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+39.43%
CURRENT VS 3Y AVG
+81.86%
CURRENT VS 5Y AVG
+102.62%
CURRENT VS 10Y AVG
+93.88%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.31
median of 840 covered companies
CURRENT VS SECTOR MEDIAN
+232.84%
vs the sector median at left
X4 Pharmaceuticals, Inc.
Market Cap
$259.85M
Quick Ratio (Acid-Test)
11.02
TTM Avg
7.90
3Y Avg
6.06
5Y Avg
5.44
Market Cap
$259.50M
Quick Ratio (Acid-Test)
24.26
TTM Avg
16.09
3Y Avg
10.56
5Y Avg
7.83
Market Cap
$258.73M
Quick Ratio (Acid-Test)
13.89
TTM Avg
8.37
3Y Avg
7.38
5Y Avg
15.00
Market Cap
$261.31M
Quick Ratio (Acid-Test)
16.00
TTM Avg
13.11
3Y Avg
8.33
5Y Avg
7.81
Market Cap
$258.00M
Quick Ratio (Acid-Test)
0.93
TTM Avg
1.36
3Y Avg
5.78
5Y Avg
8.29
Market Cap
$262.88M
Quick Ratio (Acid-Test)
4.46
TTM Avg
8.30
3Y Avg
6.73
5Y Avg
6.78
Market Cap
$256.82M
Quick Ratio (Acid-Test)
3.19
TTM Avg
3.85
3Y Avg
4.21
5Y Avg
4.14
Market Cap
$263.43M
Quick Ratio (Acid-Test)
15.82
TTM Avg
24.04
3Y Avg
14.70
5Y Avg
12.06
Market Cap
$264.03M
Quick Ratio (Acid-Test)
7.68
TTM Avg
7.37
3Y Avg
6.66
5Y Avg
5.96
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| X4 Pharmaceuticals, Inc. (XFOR) | $259.85M | 11.02 | 7.90 | 6.06 | 5.44 |
| Palisade Bio, Inc. (PALI)vs › | $259.50M | 24.26 | 16.09 | 10.56 | 7.83 |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $258.73M | 13.89 | 8.37 | 7.38 | 15.00 |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $261.31M | 16.00 | 13.11 | 8.33 | 7.81 |
| AC Immune S.A. (ACIU)vs › | $258.00M | 0.93 | 1.36 | 5.78 | 8.29 |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $262.88M | 4.46 | 8.30 | 6.73 | 6.78 |
| Anika Therapeutics, Inc. (ANIK)vs › | $256.82M | 3.19 | 3.85 | 4.21 | 4.14 |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $263.43M | 15.82 | 24.04 | 14.70 | 12.06 |
| OraSure Technologies, Inc. (OSUR)vs › | $264.03M | 7.68 | 7.37 | 6.66 | 5.96 |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $266.62M | 4.97 | 2.08 | 1.48 | 1.89 |
Quick Ratio
11.02
Excludes inventory
Current Ratio
11.30
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 11.02 |
| 2026-03-31 | 9.98 |
| 2025-12-31 | 9.98 |
| 2025-09-30 | 5.48 |
| 2025-06-30 | 3.05 |
| 2025-03-31 | 3.58 |
| 2024-12-31 | 3.33 |
| 2024-09-30 | 4.80 |
| 2024-06-30 | 6.04 |
| 2024-03-31 | 3.71 |
| 2023-12-31 | 5.34 |
| 2023-09-30 | 5.81 |
| 2023-06-30 | 6.64 |
| 2023-03-31 | 5.04 |
| 2022-12-31 | 5.76 |
| 2022-09-30 | 2.99 |
| 2022-06-30 | 2.39 |
| 2022-03-31 | 4.73 |
| 2021-12-31 | 6.27 |
| 2021-09-30 | 6.10 |
| 2021-06-30 | 7.73 |
| 2021-03-31 | 8.18 |
| 2020-12-31 | 6.97 |
| 2020-09-30 | 7.13 |
| 2020-06-30 | 10.19 |
| 2020-03-31 | 15.34 |
| 2019-12-31 | 13.68 |
| 2019-09-30 | 9.57 |
| 2019-06-30 | 7.32 |
| 2019-03-31 | 1.59 |
| 2018-12-31 | 1.18 |
| 2018-09-30 | 5.08 |
| 2018-06-30 | 5.54 |
| 2018-03-31 | 7.37 |
| 2017-12-31 | 7.45 |
| 2017-09-30 | 2.51 |
| 2017-06-30 | 4.30 |
| 2017-03-31 | 0.43 |
| 2016-03-31 | 0.00 |
